Established in 2016, Nuwacell Biotechnologies Co., Ltd. is dedicated to advancing iPSC basic research and clinical applications. We are committed to developing broadly accessible cell therapy products.

The company has strategically positioned itself across the entire iPSC technology spectrum, from upstream activities such as iPSC reprogramming library construction and clinical-grade culture reagent products to midstream efforts involving iPSC-induced differentiation of various functional cells for in vitro research, and downstream pursuits in iPSC-derived cell drug development. This comprehensive product and service system is supported by state-of-the-art, internationally leading scientific research-grade and clinical-grade stem cell R&D and production facilities. Notably, we house the largest Chinese population iPSC super donor bank in the nation.

Simultaneously, we've meticulously built an extensive invention patent portfolio, focusing on the application of iPSC technology. This portfolio encompasses iPSC reprogramming, directional induction, and differentiation of multiple functional cells, along with production processes and key raw materials.

Centering around the core technology of iPSC, Nuwacell is consistently advancing the research and development of various cell therapy pipelines in three major medical directions: Anti-inflammatory Repair, Tumor Immunotherapy, and Regenerative Medicine. Among them, both iPSC-derived Mesenchymal Stem Cell-like Cells (iMSC) and iPSC-derived Natural Killer Cells (iNK) therapeutic products have obtained Clinical Trial Implied Licenses from the China National Medical Products Administration (CDE), marking them as the first domestically approved clinical iPSC-derived MSC and NK cell therapies. The company plans to progressively submit Investigational New Drug (IND) applications for subsequent iPSC-derived cell therapies, entering the clinical trial phase, as part of our ongoing exploration of the clinical value of iPSC-derived therapeutics.